Beijing. The vaccine made by Sinopharm from China can certainly prevent transmission of crown infection. The effectiveness of Sinopharm crown infection vaccine is quite high, reaching 79%, slightly less than the vaccines made by Pfizer-BioNtech and Moderna.
Reporting from AFP on Wednesday (30/12/2020), Sinopharm crown infection vaccine is 79 percent effective according to the results of the phase 3 trial.This means that the efficacy of this vaccine is lower than competing injections developed by Pfizer-BioNTech and Moderna. Even so, it is still a potential breakthrough in the battle to contain the pandemic in Asia.
China, where the pandemic first emerged, has been racing against the West to develop its own Coronavirus vaccine. There are five vaccines that are already in large-scale phase 3 clinical trials, but none have yet been officially approved.
Wednesday's announcement (30/12/2020) is the first piece of information released regarding the efficacy of China's vaccine candidate. "The protective effect of the (Sinopharm CNBG Beijing) vaccine against the Coronavirus is 79.34 percent," says the organization of the Beijing Institute of Biological Products, a subsidiary of Sinopharm that has developed a vaccine with CNBG.
According to the statement, the crown sinopharm infection vaccine has submitted an application to the Chinese medicine controller for vaccine approval to deactivate the crown infection. This vaccine is a type of inoculation using pathogenic particles.
China has been struggling to gain international credentials for the crown infection vaccine candidate, hampered by a lack of transparency of test results. Phase 3 trials, which have to take place overseas, are progressing slowly.
This is because the "Bamboo Curtain Country" is still trying to reduce the spread of the Coronavirus within its own borders.
Meanwhile, the crown infection vaccine made in Western countries has grown rapidly with the launch and approval of the vaccine. Hundreds of millions of doses have been ordered from leading crown infection vaccine candidates, such as Pfizer-BioNTech and Moderna. The respective crown infection vaccines have an efficacy rate of 95 percent and 94 percent.
Although information is minimal and the crown infection vaccine has yet to be proven, more than one million people have received injections of vaccines that have not been approved by the Chinese government under its emergency use program. They include frontline health workers, employees of state-owned companies, and workers planning to travel abroad.
China plans to vaccinate millions more this winter ahead of Chinese New Year. Officials have pledged to increase production capacity for crown infection vaccine to more than 1 billion doses by next year.
The United Arab Emirates Bedouin approved the Sinopharm vaccine earlier this month, becoming the first foreign country to adopt the Chinese-developed Coronavirus inoculation. Beijing has pledged to distribute its vaccine at a relatively low cost.
So potentially poorer Asian countries are selected, which may have to depend on the limited distribution offered by the worldwide scheme. It also fed China diplomacy amid widespread criticism over its early handling of the outbreak that caught the attention of the United States (US) and Australia.
"We will also prioritize developing countries for vaccines. This will be done through various means, including through donations and assistance," individualized organization spokesman for the Ministry of Foreign Affairs Zhao Lijian, Friday (25/12/2020).
The vaccine from inactive crown infection is easier to distribute than the vaccine candidate from Pfizer. The vaccine produced by the US company must be stored at less than 70 degrees Celsius.
Conditions that are not possible in most developing countries. As a wave of winter infections swept across much of the world, triggering a new lockdown, and a dismal spike in the number of deaths, attention has returned to pandemic management in China.
Chinese health authorities this week said information from antibodies was circulating in Wuhan. It is estimated that the number of cases at the epicenter of the pandemic may be 10 times higher than previously reported.
About 4.4 percent of the city's 11 million residents had developed antibodies to the Coronavirus in April, according to a report by the Chinese Center for Disease Control. That is the equivalent of about 480,000 infections.
Beijing has gone to great lengths to retool the pandemic's story to its advantage. His government heralded the swift reflex of its Communist leadership in locking down the country and restarting the economy.
China is estimated to be the only major economy that recorded positive growth this year. But Beijing has been widely criticized for shutting down discussions and reports that question the official narrative set up by the government.
On Monday (28/12/2020), a Shanghai court jailed citizen journalist Zhang Zhan for four years, for reporting from Wuhan during the early months of the pandemic. US Secretary of State Mike Pompeo, who has attacked China's pandemic response, is calling for his immediate release.
"The Chinese Communist Party has once again shown it will do whatever it takes to silence those who question the official party lines," he said.
Posting Komentar